Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer

Frontiers in Oncology

Eneda Toska²  Amaia Arruabarrena-Aristorena⁵ 

[1] Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Derio, Spain;Department of Biochemistry and Molecular Biology, Johns Hopkins School of Public Health, Baltimore, MD, United States;Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States;Ikerbasque, Basque Foundation for Science, Bilbao, Spain;Traslational Prostate Cancer Research Lab, CIC bioGUNE-Basurto, Biocruces Bizkaia Health Research Institute, Derio, Spain;

关键词: breast cancer;    epigenetics;    estrogen receptor - ESR1;    endocrine therapy;    transcription factor;    chromatin regulation;   

DOI  :  10.3389/fonc.2022.924808

来源: DOAJ

【 摘 要 】

The majority of breast cancers are estrogen receptor (ER)+ and agents targeting the ER signaling pathway have markedly increased survival for women with breast cancer for decades. However, therapeutic resistance eventually emerges, especially in the metastatic setting. In the past decade disrupted epigenetic regulatory processes have emerged as major contributors to carcinogenesis in many cancer types. Aberrations in chromatin modifiers and transcription factors have also been recognized as mediators of breast cancer development and therapeutic outcome, and new epigenetic-based therapies in combination with targeted therapies have been proposed. Here we will discuss recent progress in our understanding of the chromatin-based mechanisms of breast tumorigenesis, how these mechanisms affect therapeutic response to standard of care treatment, and discuss new strategies towards therapeutic intervention to overcome resistance.

【 授权许可】

Unknown